Skip to main content

Advertisement

SpringerLink
Log in

Prognostic value of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) and aminopeptidase N/CD13 in breast cancer patients

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The aim of this study was to analyse the expression of matrix metalloproteinase-2(MMP-2), matrix metalloproteinase-9 (MMP-9) and aminopeptidase APN/CD13 in breast carcinoma samples, and their possible prognostic value in breast cancer patients. The expression of MMP-2, MMP-9 and APN/CD13 in tumor cells was analysed in 138 breast carcinomas by immunohistochemical staining of tumor cells using the semiquantitative method for the detection of cytoplasmic and membrane reaction in tumor cells as well as stromal cells positivity. MMP-2 was positive in tumor cells of 52.9% patients and in stromal cells of 74.6% patients, while MMP-9 positive tumor and stromal cells were found in 84.8 and 63.8% patients, respectively. Tumor cell APN/CD13 expression was found in 36.2% patients. Stromal cell MMP-2 expression correlated significantly with tumor size and neoangiogenesis. A positive correlation was also observed between tumor cell MMP-9 expression and hormone receptor status. Stromal cell coexpression of MMP-2/MMP-9 correlated significantly with tumor size. APN/CD13 expression in tumor cells significantly correlated with tumor type and neoangiogenesis. Overall survival was significantly shorter in patients with MMP-2, MMP-2/MMP-9 positive tumor cells, and tended to be shorter in patients with APN/CD13 positive tumor cells. Coexpression of MMP-2/MMP-9 in tumor cells was an independent risk factor for patient survival (OD = 13.9). Our results suggest that MMP-2, MMP-9, APN/CD13 expression and MMP-2/MMP-9 coexpression in combination with other standard prognostic factors can serve as a poor prognostic factor in the evaluation of breast cancer prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Strnad M, Hrabak-Žerjavić V, Šamija M. Epidemiology, prevention and early detection of breast cancer. In: Šamija M, Juzbašić S, Šeparović V, Vrdoljak VD, editors. Breast tumors. 1st ed. Zagreb: Medicinska Naklada; 2007. p. 27–32.

    Google Scholar 

  2. Lester SC, Cotran RS. The breast. In: Cotran RS, Kumar V, Robbins SLG, editors. Pathologic basis of disease. 6th ed. Philadelphia: WB Sounders; 1999. p. 1093–119.

    Google Scholar 

  3. Rosen PP. Invasive duct carcinoma, assessment of prognosis, morphologic prognostic markers and tumor growth rate. In: Rosen PP, editor. Rosen’s breast pathology. 2nd ed. Philadelphia: Lippincott Williams/Wilkins; 2001. p. 325–56.

    Google Scholar 

  4. Woessner JF, Nagase H. Matrix metalloproteinases and TIMPs (protein profile). 2nd ed. In: Woessner JF, Nagase H, editors. New York: Oxford University Press; 2000.

  5. Duffy MJ, Maguire TM, Hill A, McDermott E, Ohiggins N. Metalloproteinases: role in breast cancerogenesis, invasion and metastasis. Br Cancer Res. 2000;4:252–7.

    Article  Google Scholar 

  6. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function and biochemistry. Circ Res. 2003;2:827–39.

    Article  Google Scholar 

  7. Ross JS, Linette GP, Stec J, Clark E, Ayers M, et al. Breast cancer biomarkers and molecular medicine: part II. Expert Rev Mol Diagn. 2004;2:169–88.

    Article  Google Scholar 

  8. John A, Tuszynski G. The role of matrix metalloproteinases in tumour angiogenesis and tumor metastasis. Pathol Oncol Res. 2001;7:14–23.

    Article  PubMed  CAS  Google Scholar 

  9. Tsukamoto H, Shibata K, Kajiyama H, Terauchi M, Nawa A, Kikkawa F. Aminopeptidase N (APN)/CD13 inhibitor, Ubenimex, enhances radiation sensitivity in human cervical cancer. BMC Cancer. 2008;8:74–80.

    Article  PubMed  Google Scholar 

  10. Terauchi M, Kajiyama H, Shibata K, Ino K, Nawa A, Mizutani S, Kikkawa F. Inhibition of APN/CD13 leads to suppressed progressive potential in ovarian carcinoma cells. BMC Cancer. 2007;7:140–6.

    Article  PubMed  Google Scholar 

  11. Caudroy S, Polette M, Tournier JM, Burlet H, Toole B, Zucker S, Birembaut P. Expression of the extracellular matrix metallo-proteinase inducer (EMMPERIN) and the matrix metalloproteinase-2 in bronchopulmonary and breast lesions. J Histochem Cytochem. 1999;47:1575–80.

    Article  PubMed  CAS  Google Scholar 

  12. van Hensbergen Y, Broxterman HJ, Rana S, van Diest PJ, Duyndam MCA, et al. Reduced growth, increased vascular area and reduced response to Cisplatin in CD13-overexpressing human ovarian cancer xenografts. Clin Cancer Res. 2004;10(3):1180–91.

    Article  PubMed  Google Scholar 

  13. Bhagwat SV, Lahdenranta J, Giordano R, Arap W, Pasqualini R, Shapiro LH. CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. Blood. 2001;97(3):652–9.

    Article  PubMed  CAS  Google Scholar 

  14. Yang E, Shim JS, Woo HJ, Kim KW, Kwon HJ. Aminopeptidase N/CD13 induces angiogenesis through interaction with a pro-angiogenic protein, galectin-3. Biochem Biophys Res Commun. 2007;363:336–41.

    Article  PubMed  CAS  Google Scholar 

  15. Singer CF, Kronsteiner N, Marton E, Kubista M, Cullen KJ, et al. MMP-2 and MMP-9 expression in breast cancer-derived human fibroblasts is differentially regulated by stromal-epithelial interactions. Br Cancer Res. 2002;72:69–77.

    Article  CAS  Google Scholar 

  16. Tetu B, Trudel D, Wang CS. Proteases by reactive stromal cells in cancer: an attractive therapeutic target. Bull Cancer. 2006;93(9):944–8.

    PubMed  CAS  Google Scholar 

  17. Szabo KA, Singh G. Modulation of monocyte matrix metalloproteinase-2 by breast adenocarcinoma cells. Br Cancer Res. 2005;7:661–8.

    Article  Google Scholar 

  18. Sellers A, Reynolds JJ, Meikle MC. Neutral metallo-proteinases of rabbit bone. Separation in in latent forms of distinct enzymes that when activated degrade collagen, gelatin and proteoglycans. Biochem J. 1978;171:493–6.

    PubMed  CAS  Google Scholar 

  19. Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM. Expression of matrix metalloproteinase-2 (MMP-2) and MMP-9 in breast cancer with a special reference to activator protein-2, Her2, and prognosis. Clin Cancer Res. 2004;10:7621–8.

    Article  PubMed  CAS  Google Scholar 

  20. Leppa S, Saarto T, Vehmanen L, Blomqvist C, Elomaa I. A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma. Clin Cancer Res. 2004;3:1057–63.

    Article  Google Scholar 

  21. Huhtala P, Chow LT, Tryggvason K. Structure of the human type IV collagenase gene. J Biol Chem. 1990;265:11077–82.

    PubMed  CAS  Google Scholar 

  22. Peihong S, Perry F. Expression of nm23, MMP-2, TIMP-2 in breast neoplasm in Zhen-Zhou Center Hospital, China. Ethio Med J. 2007;45:79–83.

    Google Scholar 

  23. Ogura S, Ohdaira T, Hozumi Y, Omoto Y, Nagai H. Metastasis-related factors expressed in pT1 pN0 breast cancer: assessment of recurrence risk. J Surg Oncol. 2007;96:46–53.

    Article  PubMed  CAS  Google Scholar 

  24. Talvensaari-Mattila A, Pääkkö P, Turpeenniemi-Hujanen T. MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma. Br Cancer Res Treat. 1999;58:287–93.

    Article  CAS  Google Scholar 

  25. Fan SQ, Wei QY, Li MR, Zhang LQ, Liang QC. Expression and clinical significance of MMP-2, MMP-9, TIMP-1 and TIMP-2 in breast carcinoma. Ai Zheng. 2003;22(9):968–73.

    PubMed  CAS  Google Scholar 

  26. Shah FD, Shukla SN, Shah PM, Shukla HK, Patel PS. Clinical significance of matrix metalloproteinase 2 and 9 in breast cancer. Indian J Cancer. 2009;46(3):194–202.

    Article  PubMed  CAS  Google Scholar 

  27. Jinga DC, Blidaru A, Condrea I, Ardeleanu C, Dragomir C, et al. MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: correlations with prognostic factors. J Cell Mol Med. 2006;10(2):499–510.

    Article  PubMed  CAS  Google Scholar 

  28. Cao D, Polyak K, Halushka M, Nassar H, Kouprina N, et al. Serial analysis of gene expression of lobular carcinoma in situ identifies down regulation of claudin 4, overexpression of matrix metalloproteinase 9. Br Caner Res. 2008;10:R91.

    Article  Google Scholar 

  29. Liu SC, Yang SF, Yeh KT, Yeh CM, Chiou HL, et al. Relationships between the level of matrix metalloproteinase-2 and tumor size of breast cancer. Clin Chim Acta. 2006;371:92–6.

    Article  PubMed  CAS  Google Scholar 

  30. Talvensaari-Mattila A, Pääkkö P, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer. 2003;6:1270–5.

    Article  Google Scholar 

  31. Li HC, Cao DC, Liu Y, Hou YF, Wu J, et al. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Br Cancer Res Treat. 2004;88:75–85.

    Article  CAS  Google Scholar 

  32. Saiki I, Yoneda J, Azuma I, Fujii H, Abe F, Nakajima M, Tsuruo T. Role of aminopeptidase N (CD13) in tumor-cell invasion and extracellular matrix degradation. Int J Cancer. 2006;54(1):137–43.

    Article  Google Scholar 

  33. Martinez JM, Prieto I, Ramirez MJ, Cueva C, Alba F, Ramirez M. Amino peptidase activities in breast cancer tissue. Clin Chem. 1999;45(10):1797–802.

    PubMed  CAS  Google Scholar 

  34. Liang X, Zhao J, Hajivandi M, Wu R, Tao J, Amshey JW, Pope RM. Quantification of membrane and membrane-bound proteins in normal and malignant breast cancer cells isolated from the same patient with primary breast carcinoma. Proteome Res. 2006;5(10):2632–41.

    Article  CAS  Google Scholar 

  35. Dixon J, Kaklamanis L, Turley H, Hickson ID, Leek RD, Harris AL, Gatter KC. Expression of aminopeptidase-N (CD 13) in normal tissues and malignant neoplasms of epithelial and lymphoid origin. J Clin Pathol. 1994;47(1):43–7.

    Article  PubMed  CAS  Google Scholar 

  36. Bogenrieder T, Finstad CL, Freeman RH, Papandreou CN, Scher HI, et al. Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase IV in benign and malignant human prostate tissue. Prostate. 1997;33(4):225–32.

    Article  PubMed  CAS  Google Scholar 

  37. Ikeda N, Nakajima Y, Tokuhara T, Hattori N, Sho M, Kanehiro H, Miyake M. Clinical significance of Aminopeptidase N/CD13 expression in human pancreatic carcinoma. Clin Cancer Res. 2003;9:1503–8.

    PubMed  CAS  Google Scholar 

  38. Tokuhara T, Hattori N, Ishida H, et al. Aminopeptidase N in non-small cell lung cancer. Clin Cancer Res. 2006;12:3971–8.

    Article  PubMed  CAS  Google Scholar 

  39. Kehlen A, Lendeckel U, Dralle H, Langner J, Hoang-Vu C. Biological significance of Aminopeptidase N/CD13 in thyroid carcinomas. Cancer Res. 2003;63:8500–6.

    PubMed  CAS  Google Scholar 

  40. Hashida H, Takabayashi A, Kanai M, et al. Aminopeptidase N is involved in cell motility and angiogenesis: Its clinical significance in human colon cancer. Gastroenterology. 2002;122(2):376–86.

    Article  PubMed  CAS  Google Scholar 

  41. Pasqualini R, Koivunen E, Kain R, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 2000;60(3):722–7.

    PubMed  CAS  Google Scholar 

  42. Garde SV, Forte AJ, Ge M, Lepekhin EA, Panchal CJ, Rabbani SA, Wu JJ. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13- expressing cells and its antitumor effects. Anticancer Drugs. 2007;18:1189–200.

    Article  PubMed  CAS  Google Scholar 

  43. Wickstrom M, Viktorsson K, Lundholm L, et al. The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan. Biochem Pharmacol. 2010;79(9):1281–90.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This study was financially supported in part by the Croatian Ministry of Science, Education and Sport, Grant no. 098-0982464-2520. We thank Mrs Marta Malinar for her technical assistance and advice during the study.

Conflict of interest

None declared.

Author information

Authors and Affiliations

  1. Department of Clinical Cytology, SUNCE Polyclinic, Trnjanska Cesta 108, 10000, Zagreb, Croatia

    Irena Ranogajec

  2. Department of Pathology, Zagreb University Hospital Centre, Kišpatićeva 12, 10000, Zagreb, Croatia

    Jasminka Jakić-Razumović

  3. Department of Pathology, Dubrovnik Regional Hospital, Roka Mišetića 2, 50000, Dubrovnik, Croatia

    Velibor Puzović

  4. Division of Molecular Medicine, Laboratory of Experimental Haematology, Immunology and Oncology, Bijenička c.54, 10000, Zagreb, Croatia

    Jelka Gabrilovac

Authors
  1. Irena Ranogajec
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jasminka Jakić-Razumović
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Velibor Puzović
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jelka Gabrilovac
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Irena Ranogajec.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ranogajec, I., Jakić-Razumović, J., Puzović, V. et al. Prognostic value of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) and aminopeptidase N/CD13 in breast cancer patients. Med Oncol 29, 561–569 (2012). https://doi.org/10.1007/s12032-011-9984-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-011-9984-y

Keywords

Search

Navigation